Pharmacokinetic‐pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real‐world data
Pharmacokinetic parameters were similar to risankizumab clinical trials. K<sub>out</sub> estimates aligned with other psoriasis turnover models, highlighting the capture of disease dynamics that may be applied across drugs. This model may inform personalised dosing based on individual patient characteristics, drug exposure and response, to optimise treatment outcomes.
Authors
- C.R. Thomas (ORCID: https://orcid.org/0000-0002-8881-3393)
- Krystal Rawstron
- Zehra Arkir (ORCID: https://orcid.org/0000-0003-2513-9941)
- Richard Woolf (ORCID: https://orcid.org/0000-0003-3200-0075)
- Joseph Frank Standing (ORCID: https://orcid.org/0000-0002-4561-7173)
- Tejus Dasandi (ORCID: https://orcid.org/0000-0001-7793-2090)
- Jenny Leung
- David Baudry
- Jun Wei (ORCID: https://orcid.org/0000-0001-9950-0467)
- Bola Coker
- Chioma Nwaogu
- Jonathan Barker
- Andrew E. Pink
- Satveer K. Mahil
- Catherine H. Smith
- Kingsley Powell
- Monica Arenas‐Hernandez
Institutions
- St Thomas' Hospital (GB)
- King's College London (GB)
- Barts Health NHS Trust (GB)
- University College London (GB)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2026-02-15
- DOI
- https://doi.org/10.1002/bcp.70477
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00